Competitive Salary: F. Hoffmann-La Roche AG: The PositionComputational Biologist, Neuroscience Group LeadThe PositionThe Genentech Bioinformatics department seeks a highly motivated computational San Francisco, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionWe are seeking a talented and highly motivated Sub-Chapter Lead for the Translational Research Bioinformatics team at the Director/Senior Washington D.C. (US)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionComputational Biologist, NeuroscienceThe PositionThe Genentech Bioinformatics department seeks a highly motivated computational biologist San Francisco, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionImpact HealthcareRoche Sequencing is not only changing science, but we are changing lives! Our team is pushing the boundary of technology United States (US)

Competitive Salary: EMBL: The EBI is part of the European Molecular Biology Laboratory (EMBL) and it is a world-leading bioinformatics centre providing biological data to the s Hinxton, Cambridgeshire, England

Notice NOT-AT-22-030 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-208 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-22-010 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to establish a Data Analysis and Coordination Center (DACC) that will be part of a collaborative initiative to advance the application of multi-omic technologies to study health and disease in diverse populations. Together with the Disease Study Sites (RFA-HG-22-008) and the Omics Production Center(s) (RFA-HG-22-009), the DACC will leverage clinical conditions where multi-omic approaches are expected to be most informative to: 1) explore the use of multi-omics, integrated with phenotypic and environmental exposure data, including social determinants of health (SDOH), to detect and assess molecular profiles associated with healthy and disease states; 2) develop generalizable data harmonization, integration, and analysis methods, as well as best practices and standards for the optimal application of multi-omics; and 3) create a multi-dimensional dataset that is available to the research community. The DACC will be primarily responsible for coordinating Consortium logistics, outreach, and dissemination of findings; for managing and securing Consortium data; for creating the multi-dimensional dataset; and for coordinating and contributing to consortium-wide protocol development, data analysis, and methods development efforts. While this program may provide some insights into disease etiology, its primary goal is to validate and enhance generalizable multi-omic approaches to identify meaningful biological changes related to health and disease.

Funding Opportunity RFA-HG-22-009 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to establish Omics Production Center(s) (OPC(s)) that will be part of a collaborative initiative to advance the application of multi-omic technologies to study health and disease in diverse populations. Together with the Disease Study Sites (RFA-HG-22-008) and the Data Analysis and Coordination Center (RFA-HG-22-010), the Omics Production Center(s) will leverage clinical conditions where multi-omic approaches are expected to be most informative to: 1) explore the use of multi-omics, integrated with phenotypic and environmental exposure data, including social determinants of health (SDOH), to detect and assess molecular profiles associated with healthy and disease states; 2) develop generalizable data harmonization, integration, and analysis methods, as well as best practices and standards for the optimal application of multi-omics; and 3) create a multi-dimensional dataset that is available to the research community. The OPC(s) will be primarily responsible for using high high-throughput molecular assays to produce omics data from the biosamples provided by the Disease Study Sites (DSS, RFA-HG-22-008) and contributing to consortium-wide protocol development, data analysis, methods development, and the production of the multi-dimensional dataset. While this program may provide some insights into disease etiology, its primary goal is to validate and enhance generalizable multi-omic approaches to identify meaningful biological changes related to health and disease.

Notice NOT-DK-22-029 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-22-008 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to establish Disease Study Sites (DSS) that will be part of a collaborative initiative to advance the application of multi-omic technologies to study health and disease in diverse populations. Together with the Omics Production Centers (RFA-HG-22-009) and the Data Analysis and Coordination Center (RFA-HG-22-010), the Disease Study Sites will leverage clinical conditions where multi-omic approaches are expected to be most informative to: 1) explore the use of multi-omics, integrated with phenotypic and environmental exposure data, including social determinants of health (SDOH), to detect and assess molecular profiles associated with healthy and disease states; 2) develop generalizable data harmonization, integration, and analysis methods, as well as best practices and standards for the optimal application of multi-omics; and 3) create a multi-dimensional dataset that is available to the research community. Each DSS will be primarily responsible for proposing a study focused on a disease area for which integrative multi-omics could be used to define associations with healthy and disease states and to detect changes over time. Each DSS will utilize effective strategies to enroll and consent participants, collect phenotypic and environmental exposure data, collect samples and measures over time, and contribute to consortium-wide protocol development, data analysis, methods development, and the production of the multi-dimensional dataset. While this program may provide some insights into disease etiology, its primary goal is to validate and enhance generalizable multi-omic approaches to identify meaningful biological changes related to health and disease.

Notice NOT-GM-22-045 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-202 from the NIH Guide for Grants and Contracts

Competitive: CK Group: CK Group are currently recruiting for a Principal Bioinformatics Scientist to join an early-stage drug development company based in Cambridge on a permanent basis. The... Cambridge

Competitive: CK Group: CK Group are currently recruiting for a Principle Bioinformatics Scientist to join an early-stage drug development company based in Cambridge on a permanent basis. The... Cambridge

We will expand the frontiers of patient health through the integration of science, medicine, and service.
From Versiti - Tue, 06 Sep 2022 21:10:40 GMT - View all Milwaukee, WI jobs

Perform and develop routine and complex computational and database methods for implementation. Collaborate with principal investigator and bioinformatics team…
From Indeed - Tue, 06 Sep 2022 20:32:00 GMT - View all Milwaukee, WI jobs

Notice NOT-CA-22-125 from the NIH Guide for Grants and Contracts

Applicants should have strong scientific communication skills and scientific integrity. We also seek candidates from broad areas (e.g., biophysics, biochemistry…
From Medical College of Wisconsin - Tue, 06 Sep 2022 15:12:39 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-HD-23-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications to form Transporter Elucidation Centers (TECs) as part of a Transporter Elucidation Network (TEN). TECs funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will address key knowledge gaps in functional transport of nutrients and drugs to the developing fetus and infant through a focus on human placenta, lactating mammary gland, and developing gut. Such projects may necessitate deorphanization and characterization of understudied transporters and functional variants. The NICHD-funded TECs will work together to generate knowledge and resources that will be shared with the broader research community to advance our understanding of nutrient, drug, and supplement transport to the developing fetus and infant.